Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemoradiation for Stage I-IIIA Uterine MMMT
NCT00505492Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2002
- Primary completion
- Feb 2006
- Modality
- Nanoparticles, DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Cisplatin micelle injection (HA132), carboplatin and Paclitaxel Micelles for Injection in uterine carcinosarcoma (UCS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Overall Survival at 7 years, Progression-Free Survival at 7 years and 2 more. Started Feb 2002; status: terminated.
02
Drugs
Cisplatin micelle injection (HA132)carboplatinPaclitaxel Micelles for Injection
03
Conditions
uterine carcinosarcoma (UCS)
Beyond the preview
Go deeper on NCT00505492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00505492.